G. Verbist

发表

Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative

E. Wardelmann, K. K. van de Vijver, M. Zikan, 2017, Clinical Cancer Research.

A histological study of fetoscopic membrane defects to document membrane healing.

J. Deprest, E. Gratacós, L. Lewi, 2006, Placenta.

In vitro sealing of iatrogenic fetal membrane defects by a collagen plug imbued with fibrinogen and plasma

J. Deprest, P. Dekoninck, G. Verbist, 2013, Prenatal diagnosis.

Enhancing sealing of fetal membrane defects using tissue engineered native amniotic scaffolds in the rabbit model.

J. Deprest, L. Lewi, G. Verbist, 2006, American journal of obstetrics and gynecology.

Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas.

F. Amant, A. Coosemans, G. Verbist, 2007, European journal of cancer.

Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy

F. Amant, G. Verbist, S. Tuyaerts, 2014, Cancer Immunology, Immunotherapy.

The Use of Lymph Vessel Markers to Predict Endometrial Cancer Outcome

F. Amant, B. Calster, G. Verbist, 2010, International Journal of Gynecologic Cancer.

Porous Acellular Porcine Dermal Collagen Implants to Repair Fascial Defects in a Rat Model: Biomechanical Evaluation up to 180 Days

J. Deprest, G. Verbist, D. de Ridder, 2009, Gynecologic and Obstetric Investigation.

Tensile Strength and Host Response towards Silk and Type I Polypropylene Implants Used for Augmentation of Fascial Repair in a Rat Model

J. Deprest, G. Verbist, E. Verbeken, 2006, Gynecologic and Obstetric Investigation.

In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer

F. Amant, G. Verbist, S. Tuyaerts, 2016, International journal of molecular sciences.

Fate of collagen-based implants used in pelvic floor surgery: a 2-year follow-up study in a rabbit model.

J. Deprest, G. Verbist, D. de Ridder, 2008, American journal of obstetrics and gynecology.

A Comparative Study on Culture Conditions and Routine Expansion of Amniotic Fluid-Derived Mesenchymal Progenitor Cells

J. Deprest, J. Fryns, L. Gucciardo, 2013, Fetal Diagnosis and Therapy.

Acute Drug Effects on the Human Placental Tissue: The Development of a Placental Murine Xenograft Model

F. Amant, G. Verbist, Els Hermans, 2018, Reproductive Sciences.

The Effect of Transplacental Administration of Glucagon-Like Peptide-1 on Fetal Lung Development in the Rabbit Model of Congenital Diaphragmatic Hernia

J. Deprest, G. Verbist, J. Toelen, 2015, Fetal Diagnosis and Therapy.

Enrichment of collagen plugs with platelets and amniotic fluid cells increases cell proliferation in sealed iatrogenic membrane defects in the foetal rabbit model

J. Deprest, L. Lewi, G. Verbist, 2008, Prenatal diagnosis.

Kit Gene in Endometrial Carcinoma: An Immunohistochemical and Mutational Analysis

M. Debiec‐Rychter, F. Amant, G. Verbist, 2011, International Journal of Gynecologic Cancer.

In Vitro Validation of Survivin as Target Tumor-associated Antigen for Immunotherapy in Uterine Cancer

F. Amant, G. Verbist, S. Tuyaerts, 2015, Journal of immunotherapy.

Clinicopathologic markers of uterine leiomyosarcoma originating from smooth muscle tumors of low malignancy

I. Vergote, G. Tulunay, M. Debiec‐Rychter, 2005 .

Microsatellite Instable and Microsatellite Stable Primary Endometrial Carcinoma Cells and Their Subcutaneous and Orthotopic Xenografts Recapitulate the Characteristics of the Corresponding Primary Tumor

D. Lambrechts, F. Amant, G. Verbist, 2014, International Journal of Gynecologic Cancer.

Genetic and microscopic assessment of the human chemotherapy-exposed placenta reveals possible pathways contributive to fetal growth restriction.

F. Amant, G. Verbist, V. Brys, 2018, Placenta.

Wilms' tumor gene 1 (WT1) in endometrial carcinoma.

P. Neven, F. Amant, A. Coosemans, 2008, Gynecologic oncology.

Wilms Tumor Gene 1 (WT1) is a Prognostic Marker in High-Grade Uterine Sarcoma

B. van Calster, F. Amant, A. Coosemans, 2010, International Journal of Gynecologic Cancer.

The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer.

I. Vergote, A. Coosemans, G. Verbist, 2016, Anticancer research.

Expression of ERCC1, p53, and Class III &bgr;-Tubulin Do Not Reveal Chemoresistance in Endometrial Cancer: Results From an Immunohistochemical Study

F. Amant, G. Verbist, P. Moerman, 2011, International Journal of Gynecologic Cancer.

Increased expression of the neuroregenerative peptide galanin in the major pelvic ganglion following cavernous nerve injury.

G. Verbist, M. Albersen, T. Bivalacqua, 2014, The journal of sexual medicine.

In Vitro Generation of Murine Dendritic Cells for Cancer Immunotherapy: An Optimized Protocol.

P. Agostinis, I. Vergote, A. Coosemans, 2016, Anticancer research.

Wilms’ tumour gene 1 (WT1) positivity in endothelial cells surrounding epithelial uterine tumours

P. Neven, F. Amant, L. Moons, 2009, Histopathology.

Porous Acellular Porcine Dermal Collagen Implants to Repair Fascial Defects in a Rat Model: Biomechanical Evaluation up to 180 Days

J. Deprest, G. Verbist, D. de Ridder, 2009, Gynecologic and Obstetric Investigation.

In Vitro Validation of Survivin as Target Tumor-associated Antigen for Immunotherapy in Uterine Cancer

F. Amant, G. Verbist, S. Tuyaerts, 2015, Journal of immunotherapy.